Related Experiment Video
Updated: Sep 11, 2025
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Development of dihydroquinazoline compounds as novel therapeutics against Naegleria fowleri
Megan M Voisinet1, Caroline M Palmentiero2, Jillian E M McKeon2
1Department of Chemistry, Lake Superior State University, Sault Sainte Marie, MI 49783, United States.
Abstract:
Primary amoebic meningoencephalitis (PAM) is a brain infection caused by the free-living amoebae Naegleria fowleri. There are few viable treatment options for the infection, resulting in a >97 % fatality rate. Small molecules are being increasingly investigated as treatment options for this deadly infection. This work details the discovery of a dihydroquinazoline that was toxic to the amoeba and subsequent structure-activity relationship (SAR) development of compounds with increasingly potent activity, yielding several early lead candidates exhibiting submicromolar activity (EC50 = 0.62-0.84 μM) and limited cytotoxicity (CC50 > 10 μM).
Insights
Researchers discovered a new dihydroquinazoline compound effective against Naegleria fowleri, the cause of primary amoebic meningoencephalitis (PAM). This finding offers hope for treating this fatal brain infection with novel small molecule therapies.
Area of Science:
- Medicinal Chemistry
- Parasitology
- Neuroscience
Background:
- Primary amoebic meningoencephalitis (PAM) is a rare but almost uniformly fatal brain infection.
- Naegleria fowleri, a free-living amoeba, causes PAM, with limited therapeutic options available.
- Small molecules represent a promising avenue for developing novel treatments against PAM.
Purpose of the Study:
- To discover and develop novel small molecules targeting Naegleria fowleri.
- To identify potent and safe therapeutic candidates for primary amoebic meningoencephalitis.
Main Methods:
- Screening of small molecules for anti-Naegleria activity.
- Structure-activity relationship (SAR) studies to optimize compound potency.
- Evaluation of cytotoxicity against mammalian cells.
Main Results:
- Discovery of a dihydroquinazoline derivative with significant toxicity against Naegleria fowleri.
- Identification of early lead candidates with submicromolar EC50 values (0.62-0.84 μM).
- Demonstrated limited cytotoxicity (CC50 > 10 μM) for the lead compounds.
Conclusions:
- Dihydroquinazoline compounds show potential as effective treatments for primary amoebic meningoencephalitis.
- Optimized compounds exhibit potent anti-amoebic activity with a favorable safety profile.
- Further development of these small molecules could lead to a viable therapy for this deadly infection.
